Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on rare diseases, has announced its participation in two upcoming investor conferences in September 2024. The company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 at 10:00 a.m. ET and the Cantor Global Healthcare Conference 2024 on September 17 at 1:55 p.m. ET, both in New York, NY.
Investors can access live audio webcasts of these presentations through the company's website. Amicus Therapeutics is dedicated to discovering, developing, and delivering novel high-quality medicines for people living with rare diseases. The company emphasizes its commitment to advancing a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.
Amicus Therapeutics (Nasdaq: FOLD), un'azienda biotecnologica globale focalizzata sulle malattie rare, ha annunciato la sua partecipazione a due prossime conferenze per investitori a settembre 2024. L'azienda presenterà alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley il 5 settembre alle 10:00 ora orientale e alla Conferenza Globale sulla Salute di Cantor 2024 il 17 settembre alle 13:55 ora orientale, entrambe a New York, NY.
Gli investitori possono accedere a webcast audio dal vivo di queste presentazioni tramite il sito web dell'azienda. Amicus Therapeutics è dedicata alla scoperta, allo sviluppo e alla fornitura di nuovi farmaci di alta qualità per le persone affette da malattie rare. L'azienda sottolinea il proprio impegno nell'avanzare un portafoglio di farmaci all'avanguardia, di prima o migliore classe per le malattie rare.
Amicus Therapeutics (Nasdaq: FOLD), una empresa biotecnológica global centrada en enfermedades raras, ha anunciado su participación en dos conferencias de inversores que se celebrarán en septiembre de 2024. La empresa presentará en la 22ª Conferencia Anual de Atención Médica Global de Morgan Stanley el 5 de septiembre a las 10:00 a.m. ET y en la Conferencia Global de Atención Médica de Cantor 2024 el 17 de septiembre a la 1:55 p.m. ET, ambas en Nueva York, NY.
Los inversores pueden acceder a transmisiones web de audio en vivo de estas presentaciones a través del sitio web de la empresa. Amicus Therapeutics se dedica a descubrir, desarrollar y entregar nuevos medicamentos de alta calidad para las personas que viven con enfermedades raras. La empresa enfatiza su compromiso de avanzar en un pipeline de medicamentos de vanguardia, de primera o mejor clase para enfermedades raras.
아미쿠스 테라퓨틱스(상장 코드: FOLD), 희귀 질환에 중점을 둔 글로벌 생명공학 회사가 2024년 9월에 열릴 두 개의 투자자 회의에 참여한다고 발표했습니다. 이 회사는 9월 5일 오전 10시(동부 표준시)에 모건 스탠리 제22회 글로벌 헬스케어 회의에서 발표할 예정이며, 9월 17일 오후 1시 55분(동부 표준시)에 칸토 글로벌 헬스케어 회의 2024에서도 발표할 예정입니다. 두 컨퍼런스 모두 뉴욕에서 열립니다.
투자자들은 회사 웹사이트를 통해 이러한 발표의 실시간 오디오 웹캐스트에 접근할 수 있습니다. 아미쿠스 테라퓨틱스는 희귀 질환 환자들을 위한 새로운 고품질 의약품의 발견, 개발 및 제공에 전념하고 있습니다. 이 회사는 희귀 질환을 위한 최첨단, 최초 또는 최고급 의약품을 발전시키려는 자신의 헌신을 강조합니다.
Amicus Therapeutics (Nasdaq: FOLD), une entreprise biopharmaceutique mondiale axée sur les maladies rares, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. L'entreprise présentera à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 5 septembre à 10h00 (heure de l'Est) et à la Conférence Mondiale sur la Santé de Cantor 2024 le 17 septembre à 13h55 (heure de l'Est), toutes deux à New York, NY.
Les investisseurs peuvent accéder à des webcasts audio en direct de ces présentations via le site web de l'entreprise. Amicus Therapeutics se consacre à la découverte, au développement et à la fourniture de nouveaux médicaments de haute qualité pour les personnes vivant avec des maladies rares. L'entreprise souligne son engagement à faire progresser un portefeuille de médicaments innovants, de première ou de meilleure classe, pour les maladies rares.
Amicus Therapeutics (Nasdaq: FOLD), ein globales Biotechnologieunternehmen, das sich auf seltene Krankheiten spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird am 5. September um 10:00 Uhr ET auf der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley und am 17. September um 13:55 Uhr ET auf der Cantor Global Healthcare Conference 2024 in New York, NY, präsentieren.
Investoren können über die Unternehmenswebsite auf Live-Audio-Webcasts dieser Präsentationen zugreifen. Amicus Therapeutics widmet sich der Entdeckung, Entwicklung und Bereitstellung neuartiger, hochwertiger Medikamente für Menschen mit seltenen Krankheiten. Das Unternehmen betont sein Engagement zur Förderung eines Portfolios von innovativen Medikamenten der ersten oder besten Klasse für seltene Krankheiten.
- None.
- None.
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
- Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Thursday, September 5, 2024, at 10:00 a.m. ET
- Cantor Global Healthcare Conference 2024 in New York, NY on Tuesday, September 17, 2024, at 1:55 p.m. ET
A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When and where will Amicus Therapeutics (FOLD) present at investor conferences in September 2024?
How can investors access Amicus Therapeutics' (FOLD) presentations at the September 2024 conferences?
What is the main focus of Amicus Therapeutics (FOLD) as a biotechnology company?
What is Amicus Therapeutics' (FOLD) commitment regarding its pipeline for rare diseases?
